{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-278805","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.071326+00:00","generated_at":"2026-05-16T20:27:02.529261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027","bullets":["Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.","Cash and equivalents $49.0M as of Sep 30, 2025, expected to fund operations into 2027.","Net loss $7.4M ($0.60 per share) vs $17.6M ($1.46 per share) in Q3 2024, driven by lower R&D spend.","R&D expenses decreased to $3.6M from $14.3M; G&A to $4.0M from $4.5M year-over-year.","Emerging signs of clinical activity observed; preliminary PK shows steady-state drug concentration achieved 9 weeks earlier with loading regimen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-278805","json":"https://secwatch.observer/filing/0001193125-25-278805.json","markdown":"https://secwatch.observer/filing/0001193125-25-278805.md","text":"https://secwatch.observer/filing/0001193125-25-278805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/0001193125-25-278805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/qttb-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:27:02.529261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}